1. Home
  2. ACRS vs BRLS Comparison

ACRS vs BRLS Comparison

Compare ACRS & BRLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • BRLS
  • Stock Information
  • Founded
  • ACRS 2012
  • BRLS 2019
  • Country
  • ACRS United States
  • BRLS Canada
  • Employees
  • ACRS N/A
  • BRLS N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • BRLS
  • Sector
  • ACRS Health Care
  • BRLS
  • Exchange
  • ACRS Nasdaq
  • BRLS NYSE
  • Market Cap
  • ACRS 127.6M
  • BRLS 130.4M
  • IPO Year
  • ACRS 2015
  • BRLS N/A
  • Fundamental
  • Price
  • ACRS $1.26
  • BRLS $6.01
  • Analyst Decision
  • ACRS Strong Buy
  • BRLS
  • Analyst Count
  • ACRS 7
  • BRLS 0
  • Target Price
  • ACRS $10.67
  • BRLS N/A
  • AVG Volume (30 Days)
  • ACRS 801.8K
  • BRLS 881.0
  • Earning Date
  • ACRS 05-08-2025
  • BRLS 05-20-2025
  • Dividend Yield
  • ACRS N/A
  • BRLS N/A
  • EPS Growth
  • ACRS N/A
  • BRLS N/A
  • EPS
  • ACRS N/A
  • BRLS N/A
  • Revenue
  • ACRS $17,777,000.00
  • BRLS $27,668,894.00
  • Revenue This Year
  • ACRS N/A
  • BRLS N/A
  • Revenue Next Year
  • ACRS $425.96
  • BRLS N/A
  • P/E Ratio
  • ACRS N/A
  • BRLS N/A
  • Revenue Growth
  • ACRS N/A
  • BRLS N/A
  • 52 Week Low
  • ACRS $0.95
  • BRLS $3.88
  • 52 Week High
  • ACRS $5.17
  • BRLS $10.75
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 43.64
  • BRLS 53.66
  • Support Level
  • ACRS $1.20
  • BRLS $5.65
  • Resistance Level
  • ACRS $1.46
  • BRLS $5.98
  • Average True Range (ATR)
  • ACRS 0.11
  • BRLS 0.04
  • MACD
  • ACRS 0.02
  • BRLS 0.02
  • Stochastic Oscillator
  • ACRS 41.77
  • BRLS 87.80

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About BRLS BOREALIS FOODS INC

Borealis Foods Inc is a food technology company that has developed high-quality, affordable, sustainable, and nutritious ready-to-eat meals. It is a mission-driven company committed to utilizing its products to help solve national and global food security and nutrition challenges. Its commitment to nutrition, affordability, and sustainability reflects its goal of positively impacting both human life and the planet. Through the development and launch of its ready-made ramen, featuring 20 grams of complete plant-based protein per serving, Borealis is developing advanced solutions to address global food challenges.

Share on Social Networks: